Epigenetics Drugs and Diagnostic Technologies Market Research Report Information by Drug Type (DNA Methyltransferases (DNMTs) Inhibitors [Azacitidine, Decitabine, and Others], Histone Deacetylases (HDACs) Inhibitors [Vorinostat, Romidepsin, and Others], Histone Methyltransferase (HMT) Inhibitors, and Others), By Diagnostic Technologies (DNA Methylation, Histone Modification Analysis, and Others), By Application (Oncology, Neurology, Autoimmune Diseases, and Others), By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and By Re

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Technique

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE

6.1. Overview

6.2. DNA Methyltransferases (DNMTs) Inhibitors

6.2.1. Azacitidine

6.2.2. Decitabine

6.2.3. Others

6.3. Histone Deacetylases (HDACs) Inhibitors

6.3.1. Vorinostat

6.3.2. Romidepsin

6.3.3. Others

6.4. Histone Methyltransferase (HMT) inhibitors

6.5. Others

7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES

7.1. Overview

7.2. DNA Methylation

7.3. Histone Modification Analysis

7.4. Others

8. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION

8.1. Overview

8.2. Oncology

8.3. Neurology

8.4. Autoimmune Diseases

8.5. Others

9. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

9.3. Diagnostic Laboratories

9.4. Others

10. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION

10.1. Overview

10.1. North America

10.1.1. US

10.1.2. Canada

10.2. Europe

10.2.1. Germany

10.2.2. France

10.2.3. UK

10.2.4. Italy

10.2.5. Spain

10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China

10.3.2. India

10.3.3. Japan

10.3.4. South Korea

10.3.5. Australia

10.3.6. Rest of Asia-Pacific

10.4. Rest of the World

10.4.1. Middle East

10.4.2. Africa

10.4.3. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Epigenetics Drugs and Diagnostic Technologies Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Epigenetics Drugs and Diagnostic Technologies Market

11.7. Key developments and Growth Strategies

11.7.1. New Product Launch

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2022

11.8.2. Major Players R&D Expenditure. 2022

12. COMPANY PROFILES

12.1. Hologic, Inc.

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Gilead Sciences, Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Products Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Celleron Therapeutics

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Products Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Products Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. AstraZeneca PLC

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Products Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. LISEN lmprinting Diagnostics

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Products Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Salarius Pharmaceuticals, Inc.

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Products Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Jubilant Therapeutics

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Products Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Oryzon Genomics

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Products Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Epiaxis Therapeutics

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Products Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SYNOPSIS, 2019–2032

TABLE 2 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, ESTIMATES & FORECAST, 2019–2032 (USD BILLION)

TABLE 3 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 6 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 7 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 8 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 9 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 10 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 11 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 12 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 13 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 14 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 15 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 16 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 17 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 18 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 19 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 20 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 21 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 22 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 23 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 24 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 25 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 26 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 1 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 2 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 3 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 4 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 5 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 6 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 7 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 8 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 9 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 10 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 11 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 12 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 13 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 14 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 15 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 16 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 17 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 18 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 19 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 20 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 21 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 22 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 23 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 24 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 25 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 26 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 27 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 28 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 29 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 30 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 31 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 32 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 33 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 34 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 35 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 36 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 37 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 38 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 39 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 40 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 41 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 42 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 43 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 44 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 45 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 46 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 47 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 48 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 49 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 50 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 51 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 52 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 53 JAPAN: EPIG